Identifying Molecular Subtypes and 6-Gene Prognostic Signature Based on Hypoxia for Optimizing Targeted Therapies in Non-Small Cell Lung Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers — a different disease. Nat Rev Cancer. 2007;7(10):778–790. doi:10.1038/nrc2190
   PubMed Web of Science ®Google Scholar
• Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2(8):1014–1022. doi:10.1001/jamaoncol.2016.0173
   PubMed Web of Science ®Google Scholar
• Bhandari V, Hoey C, Liu LY, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet. 2019;51(2):308–318. doi:10.1038/s41588-018-0318-2
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res. 2016;57 Suppl 1:i90–i98. doi:10.1093/jrr/rrw007
   PubMed Web of Science ®Google Scholar
• Ren W, Mi D, Yang K, et al. The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis. Swiss Med Wkly. 2013;143:w13855. doi:10.4414/smw.2013.13855
   PubMed Web of Science ®Google Scholar
• Salem A, Asselin MC, Reymen B, et al. Targeting hypoxia to improve non–small cell lung cancer outcome. J Natl Cancer Inst. 2018;110:14–30. doi:10.1093/jnci/djx160
   Google Scholar
• Tharmalingham H, Hoskin P. Clinical trials targeting hypoxia. Br J Radiol. 2019;92(1093):20170966. doi:10.1259/bjr.20170966
   PubMed Web of Science ®Google Scholar
• Chang WH, Forde D, Lai AG. A novel signature derived from immunoregulatory and hypoxia genes predicts prognosis in liver and five other cancers. J Transl Med. 2019;17(1):14. doi:10.1186/s12967-019-1775-9
   PubMed Web of Science ®Google Scholar
• Mo Z, Yu L, Cao Z, Hu H, Luo S, Zhang S. Identification of a hypoxia-associated signature for lung adenocarcinoma. Front Genet. 2020;11:647. doi:10.3389/fgene.2020.00647
   PubMed Web of Science ®Google Scholar
• Sun J, Zhao T, Zhao D, et al. Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients. Ther Adv Med Oncol. 2020;12:1758835920937904. doi:10.1177/1758835920937904
   Web of Science ®Google Scholar
• Carvalho S, Troost EG, Bons J, Menheere P, Lambin P, Oberije C. Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – a survival model with external validation. Radiother Oncol. 2016;119:487–494. doi:10.1016/j.radonc.2016.04.024
   PubMed Web of Science ®Google Scholar
• Shi Y, Fan S, Wu M, et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019;10(1):4892. doi:10.1038/s41467-019-12801-6
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (Oxford, England). 2004;20(3):307–315. doi:10.1093/bioinformatics/btg405
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics (Oxford, England). 2010;26(12):1572–1573. doi:10.1093/bioinformatics/btq170
   PubMed Web of Science ®Google Scholar
• Maaten LVD. Accelerating t-SNE using tree-based algorithms. J Mach Learn Res. 2014;15:3221–3245.
   Web of Science ®Google Scholar
• Roh W, Chen PL, Reuben A, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9. doi:10.1126/scitranslmed.aah3560
   Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. doi:10.1186/s13059-016-1070-5
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife. 2017;6. doi:10.7554/eLife.26476
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9:e107468. doi:10.1371/journal.pone.0107468
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhou Y, Qu W, Deng M, Zhang C. A Lasso regression model for the construction of microRNA-target regulatory networks. Bioinformatics (Oxford, England). 2011;27(17):2406–2413. doi:10.1093/bioinformatics/btr410
   PubMed Web of Science ®Google Scholar
• Zhang Z. Variable selection with stepwise and best subset approaches. Ann Transl Med. 2016;4(7):136. doi:10.21037/atm.2016.03.35
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830.e814. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Xie Y, Shi X, Sheng K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019;19(2):783–791. doi:10.3892/mmr.2018.9713
   PubMed Web of Science ®Google Scholar
• Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013;341(1):63–72. doi:10.1016/j.canlet.2012.11.019
   PubMed Web of Science ®Google Scholar
• Ishida T, Hijioka H, Kume K, Miyawaki A, Nakamura N. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. Oncol Lett. 2013;6(5):1201–1206. doi:10.3892/ol.2013.1549
   PubMed Web of Science ®Google Scholar
• Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A. 2008;105(17):6392–6397. doi:10.1073/pnas.0802047105
   PubMed Web of Science ®Google Scholar
• Lin YT, Wu KJ. Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-β signaling. J Biomed Sci. 2020;27:39. doi:10.1186/s12929-020-00632-3
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36(10):1085–1093. doi:10.1093/carcin/bgv123
   PubMed Web of Science ®Google Scholar
• Labiano S, Palazon A, Melero I. Immune response regulation in the tumor microenvironment by hypoxia. Semin Oncol. 2015;42(3):378–386. doi:10.1053/j.seminoncol.2015.02.009
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010
   PubMed Web of Science ®Google Scholar
• Henze AT, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest. 2016;126:3672–3679. doi:10.1172/JCI84427
   PubMed Web of Science ®Google Scholar
• Ji S, Zhang B, Liu J, et al. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett. 2016;374(1):127–135. doi:10.1016/j.canlet.2016.01.054
   PubMed Web of Science ®Google Scholar
• Dai L, Pan G, Liu X, et al. High expression of ALDOA and DDX5 are associated with poor prognosis in human colorectal cancer. Cancer Manag Res. 2018;10:1799–1806. doi:10.2147/CMAR.S157925
   PubMed Web of Science ®Google Scholar
• Chang YC, Chan YC, Chang WM, et al. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression. Cancer Lett. 2017;403:28–36. doi:10.1016/j.canlet.2017.06.001
   PubMed Web of Science ®Google Scholar
• Nakamura R, Kataoka H, Sato N, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 2005;96:42–47. doi:10.1111/j.1349-7006.2005.00007.x
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Tei M, Uemura M, et al. Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer. Int J Oncol. 2013;42(2):549–555. doi:10.3892/ijo.2012.1750
   PubMed Web of Science ®Google Scholar
• Li N, Spetz MR, Ho M. The role of glypicans in cancer progression and therapy. J Histochem Cytochem. 2020;68(12):841–862. doi:10.1369/0022155420933709
   PubMed Web of Science ®Google Scholar
• Munir J, Van Ngu T, Na Ayudthaya PD, Ryu S. Downregulation of glypican-4 facilitates breast cancer progression by inducing cell migration and proliferation. Biochem Biophys Res Commun. 2020;526(1):91–97. doi:10.1016/j.bbrc.2020.03.064
   PubMed Web of Science ®Google Scholar
• Fang Y, Shen ZY, Zhan YZ, et al. CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. Nat Commun. 2019;10:3981. doi:10.1038/s41467-019-11662-3
   PubMed Web of Science ®Google Scholar
• Hayashida T, Takahashi F, Chiba N, et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A. 2010;107(3):1100–1105. doi:10.1073/pnas.0912710107
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Chiang AC, Zhang XH, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009;138:51–62. doi:10.1016/j.cell.2009.04.030
   PubMed Web of Science ®Google Scholar
• Zhou J, Kwak KJ, Wu Z, et al. PLAUR confers resistance to gefitinib through EGFR/P-AKT/Survivin signaling pathway. Cell Physiol Biochem. 2018;47(5):1909–1924. doi:10.1159/000491071
   PubMedGoogle Scholar